Brief: Theratechnologies Initiates Increased Dose Level In Phase 1 Clinical Trial Of Sudocetaxel Zendusortide In Advanced Ovarian Cancer
21/03/2024 11:41
March 21 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES INITIATES INCREASED DOSE LEVEL IN PHASE
1
CLINICAL TRIAL OF SUDOCETAXEL ZENDUSORTIDE IN ADVANCED OVARIAN
CANCER
* THERATECHNOLOGIES INC -FIRST PATIENT OUT OF SIX ALREADY
ENROLLED
AND TREATED WITH INITIAL DOSE OF 2.50 MG/KG/DOSE
Source text for Eikon: ID:nGNX7nDb1X
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process